TARRYTOWN, N.Y. & BOSTON--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile (C. difficile). C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a serious global public health challenge. In a well-established hamster model of C. difficile-associated disease (CDAD), treatment with Progenics’ antitoxin antibodies resulted in 95% survival versus 0% survival for standard antibiotic treatment. The data are being presented at the 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston, MA.
